Longitude Capital Partners III, LLC

Filings by Longitude Capital Partners III, LLC span 3 companies, the busiest being Sierra Oncology, Inc., Inozyme Pharma, Inc. and Talaris Therapeutics, Inc. Between 11 May 2021 and 27 April 2022, the trades on record add up to 5 filings.

On the market, this insider has only ever bought: 2 purchases, €8.8M in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 1 share grant. 2022 to date brings 2 purchases and no sales.

On 29 April 2022 came the latest disclosure, a transaction in Sierra Oncology, Inc. The last insider purchase was made public on 21 April 2022, 1,641 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.